Corvidia Stock

corvidiatx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $91.8MM

Corvidia Therapeutics is a developer of precision therapies using the science of genomics in new ways.

Register To Buy and Sell Shares

For more details on financing and valuation for Corvidia, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Corvidia’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Corvidia.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Nicholas Coscia
Controller
GaoZhong Zhu
Vice President & Head of Pharmaceutical Development and Manufacturing
Marc de Garidel
Chief Executive Officer & Board Member
Matt Devalaraja Ph.D
Co-Founder, Executive Vice President & Head of Research & Development
Douglas Kling
Senior Vice President, Clinical Operations
Michael Davidson MD
Co-Founder, Board Member & Chief Scientific Officer
Ram Aiyar Ph.D
Co-Founder, Executive Vice President & Head of Business Development
Kurt Herzog
Senior Business Analyst

Board Members

Aaron Kantoff
Apple Tree Partners
Marc de Garidel
Sylvie Grégoire Ph.D
Graziano Seghezzi Ph.D
Sofinnova Partners
Michael Davidson MD
Karim Helmy Ph.D
Venrock
Seth Harrison MD
Apple Tree Partners
Tyrell Rivers Ph.D

Frequently Asked Questions About Corvidia’s Stock

plusminus
Can you buy Corvidia’s stock?
Corvidia is not publicly traded on NYSE or NASDAQ in the U.S. To buy Corvidia’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Corvidia’s stock?
Yes, you can sell stock of a private company like Corvidia. Forge can help you sell your Corvidia stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Corvidia’s stock price?
Corvidia is a privately held company and therefore does not have a public stock price. However, you may access Corvidia’s private market stock price with Forge Data.
plusminus
What is Corvidia’s stock ticker symbol?
Corvidia does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Corvidia Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in...
Corvidia Therapeutics Raises $26M in Series A Funding |FinSMEs
Corvidia Therapeutics, a Boston, MA-based biotechnology company focused on the development of precision cardiovascular therapies, raised $26m in Series A funding. The round was co-led by Sofinnova Partners and Apple Tree Partners. In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi, Partner at Sofinnova …
Updated on: Apr 15, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.